FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer

February 28, 2019 – The FDA has approved subcutaneous use of trastuzumab and hyaluronidase-oysk injection in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen. The approval is … (leggi tutto)